Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

NCT07570810 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Obesity
Non-alcoholic Fatty Liver Disease

Interventions

DRUG: CS0159
DRUG: CS0159 placebo
DRUG: Semaglutide

Sponsor

Shanghai Jiao Tong University School of Medicine